| Grant ID | RP160827 |
| Awarded On | May 18, 2016 |
| Title | A platform technology for the isolation of anti-cancer monoclonal antibodies from chickens |
| Program | Academic Research |
| Award Mechanism | High Impact/High Risk |
| Institution/Organization | Texas A&M University System Health Science Center |
| Principal Investigator/Program Director | Zhilei Chen |
| Cancer Sites | All Sites |
| Contracted Amount | $200,000 |
| Lay Summary |
Antibody-based therapy has transformed modern cancer treatment. However, to realize the full potential of antibodies in the fight against cancer, new and better cancer-cell-specific antibodies are urgently needed. All current therapeutic antibodies are derived from murine host. Mouse and human are both mammals and many of our proteins share high homology. Homologous regions likely play important cellular functions and thus are preserved through evolution. Hence, homologous regions on a cancer receptor are potentially good targets for cancer therapy. However, animals cannot generate antibodies against proteins of their own (a.k.a. “anti-self”). Consequently, it is not possible to obtain murin... |